AVX502 influenza alphavaccine: Phase I data

In a double-blind, placebo-controlled, Phase I trial in 216 healthy volunteers, subcutaneous and intramuscular injections of AVX502 were safe and well tolerated. Among 38 subjects with prevaccination ...